Compare Charles River Laboratories Intl. Inc (CRL) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs TKO Group Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.69 (market cap $14.23B), while TKO Group Holdings Inc trades at $178.8 (market cap $13.28B). The key difference: Charles River Laboratories Intl. Inc and TKO Group Holdings Inc are close in size by market cap, and TKO Group Holdings Inc pays a 1.74% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and TKO Group Holdings Inc for 30 Days on average.
| CRL | TKO | |
|---|---|---|
Market Cap | $14.23B | $13.28B |
Volume | 1,176,885 | 857,653 |
Sector | Health | Media |
52-Week High | $310.77 | $224.96 |
52-Week Low | $149.93 | $175.58 |
Typical Hold Time | 33 Days | 30 Days |
Enterprise Value | $17.06B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
TKO trades at $181.54, up 1.62% on the day, but technical indicators signal a bearish trend. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating on revenue, and raised full-year guidance. Strong analyst sentiment persists with an 89% buy rating and a $227 consensus price target, suggesting significant upside. Recent news highlights media rights strength and a declared dividend.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but risks include execution on guidance and competitive pressures. The stock's high P/E of 63.73 indicates premium valuation, requiring sustained growth to justify. Near-term price action may be influenced by technical resistance and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
